Real‐World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small‐Cell Lung Cancer Receiving Third‐Line Treatment
These RW findings validate 3L results from clinical trials, demonstrating the limited clinical benefits with current therapies in 3L ES SCLC, and highlighting the urgent need for novel therapies that improve outcomes in this difficult-to-treat patient population.
Authors
- Jair Bar (ORCID: https://orcid.org/0000-0002-1224-3646)
- Qingqing Xu (ORCID: https://orcid.org/0000-0002-7703-5872)
- Pooja Hingorani (ORCID: https://orcid.org/0000-0002-4772-7456)
- Neal Ready
- Alice Virani (ORCID: https://orcid.org/0000-0003-1374-3172)
- Sudeep Karve
Institutions
- Tel Aviv University (IL)
- Duke University (US)
- Sheba Medical Center (IL)
- AbbVie (United States) (US)
- Duke Medical Center (US)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/cnr2.70289
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00